Precision Oncology: 2023 in Review
Yonina R. Murciano‐Goroff(Memorial Sloan Kettering Cancer Center), Sarah P. Suehnholz(Memorial Sloan Kettering Cancer Center), Alexander Drilon(Memorial Sloan Kettering Cancer Center), Debyani Chakravarty(Memorial Sloan Kettering Cancer Center)
Cited by 37Open Access
Abstract
SUMMARY: This article presents a review of recent major advances in precision oncology and the future implications of these advances, specifying the iterative progress achieved from the end of 2022 through 2023. We discuss the different classes of precision oncology drugs and associated biomarkers as well as the improvements in clinical trial design that have enabled the efficient testing of these drugs.
Related Papers
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal et al.|New England Journal of Medicine|2023|699
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al.|Journal of Clinical Oncology|2022|684
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle, Sameek Roychowdhury, Robin Kate Kelley et al.|The Lancet. Gastroenterology & hepatology|2021|420